Expert Interview
Discussing Fusion Pharma’s acquisition of 225Ac-PSMA I&T in treating prostate cancer
Ticker(s): FUSNInstitution: Mayo Clinic (formerly Tulane)
- Professor of Medicine, Urology, and Radiology at the Mayo Clinic (former Medical Director, Tulane Cancer Center & Associate Dean for Oncology Tulane Medical School).
- Treats 1000 patients with prostate cancer.
- Research focuses broadly on prostate cancer, predominantly in those patients who failed initial therapies; lead author on two studies pivotal for FDA drug approval in prostate cancer and has been the PI or co-PI on a number of prospective international clinical trials evaluating new therapies for patients with advanced prostate cancer.
An oncologist with experience in treating prostate cancer.
Added By: slingshot_insightsHow does 225Ac-PSMA I&T work?
What is the mechanism of action of 225Ac-PSMA I&T in treating prostate cancer?
How does 225Ac-PSMA I&T compare to other treatments for prostate cancer?
Could you please discuss the results for 225Ac-PSMA I&T in treating prostate cancer?
What is the potential for 225Ac-PSMA I&T to be used as a first-line treatment for prostate cancer?
What is the potential for 225Ac-PSMA I&T be used in combination with other prostate cancer treatments?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
